HLCR 012
Alternative Names: HLCR-012Latest Information Update: 05 Apr 2022
At a glance
- Originator Healios
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Sep 2021 Preclinical trials in Dry age-related macular degeneration in Europe, USA (Intraocular) before September 2021 (Healios pipeline, September 2021)
- 13 Jun 2019 Sumitomo Dainippon Pharma concludes an agreement to make changes to the original agreements with Healios for eye diseases